Morgan Stanley
STOK icon

Morgan Stanley’s Stoke Therapeutics STOK Stock Holding History

Morgan Stanley’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113M Buy
3,452,795
+29,515
+0.9% +$947K 0.01% 1465
2026
Q1 		$111M Sell
3,423,280
-122,878
-3% -$4.03M 0.01% 1353
2025
Q4 		$113M Buy
3,546,158
+9,108
+0.3% +$274K 0.01% 1353
2025
Q3 		$83.1M Sell
3,537,050
-36,926
-1% -$633K 0.01% 1569
2025
Q2 		$40.6M Sell
3,573,976
-16,849
-0.5% -$160K ﹤0.01% 2118
2025
Q1 		$23.9M Buy
3,590,825
+153,581
+4% +$1.43M ﹤0.01% 2520
2024
Q4 		$37.9M Sell
3,437,244
-768,063
-18% -$9.44M ﹤0.01% 2091
2024
Q3 		$51.7M Buy
4,205,307
+726,510
+21% +$10.3M ﹤0.01% 1795
2024
Q2 		$47M Sell
3,478,797
-546,205
-14% -$7.38M ﹤0.01% 1819
2024
Q1 		$54.3M Buy
4,025,002
+654,640
+19% +$3.97M ﹤0.01% 1685
2023
Q4 		$17.7M Buy
3,370,362
+456,578
+16% +$1.95M ﹤0.01% 2814
2023
Q3 		$11.5M Sell
2,913,784
-7,292
-0.2% -$47.9K ﹤0.01% 3001
2023
Q2 		$31.1M Sell
2,921,076
-3,452
-0.1% -$36.7K ﹤0.01% 2029
2023
Q1 		$24.4M Buy
2,924,528
+470,842
+19% +$4.25M ﹤0.01% 2209
2022
Q4 		$22.6M Sell
2,453,686
-158,356
-6% -$1.65M ﹤0.01% 2212
2022
Q3 		$33.5M Sell
2,612,042
-3,832
-0.1% -$61.1K ﹤0.01% 1662
2022
Q2 		$34.6M Buy
2,615,874
+63,745
+2% +$968K ﹤0.01% 1703
2022
Q1 		$53.7M Buy
2,552,129
+2,428,519
+1,965% +$48.6M 0.01% 1259
2021
Q4 		$2.97M Sell
123,610
-18,115
-13% -$432K ﹤0.01% 4249
2021
Q3 		$3.61M Sell
141,725
-52,765
-27% -$1.47M ﹤0.01% 4060
2021
Q2 		$6.55M Sell
194,490
-22,445
-10% -$793K ﹤0.01% 3489
2021
Q1 		$8.43M Buy
216,935
+205,971
+1,879% +$11.7M ﹤0.01% 2827
2020
Q4 		$679K Buy
10,964
+7,899
+258% +$362K ﹤0.01% 4889
2020
Q3 		$102K Sell
3,065
-47,525
-94% -$1.36M ﹤0.01% 5429
2020
Q2 		$1.21M Buy
50,590
+45,489
+892% +$1.08M ﹤0.01% 4026
2020
Q1 		$117K Sell
5,101
-12,398
-71% -$306K ﹤0.01% 5124
2019
Q4 		$496K Buy
17,499
+11,459
+190% +$288K ﹤0.01% 4927
2019
Q3 		$130K Buy
6,040
+2,490
+70% +$69.4K ﹤0.01% 5347
2019
Q2 		$104K Buy
+3,550
New +$95.3K ﹤0.01% 5303

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley's STOK Position: Q2 2026 in Review

Morgan Stanley increased its Stoke Therapeutics (STOK) stake by 0.86% in Q2 2026, buying an estimated $947K and bringing the position to 3,452,795 shares worth $113M. The position accounts for 0.01% of the portfolio, ranked #1465.

Morgan Stanley first reported a position in STOK in Q2 2019 and has held it in 29 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Morgan Stanley held 3,452,795 shares of Stoke Therapeutics worth $113M as of Q2 2026.
  • Morgan Stanley bought 29,515 Stoke Therapeutics shares in Q2 2026, an estimated $947K.
  • Stoke Therapeutics made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1465 holding.
  • Morgan Stanley first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.